Pioneering tRNA therapeutics, Michelle Werner, CEO, Alltrna & CEO-Partner, Flagship Pioneering
Synopsis: Michelle Werner is the CEO of Alltrna and a CEO-Partner at Flagship Pioneering. Alltrna is the world’s first tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to...
27 Sep 202329min
Breaking new ground in the treatment of fibrosis, Bernard Coulie, President & CEO, Pliant Tx
Synopsis: Bernard Coulie is the President and CEO of Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progres...
20 Sep 202333min
Transforming medicine through precision epigenomic control, Mahesh Karande, Pres. & CEO, Omega Tx
Synopsis: Mahesh Karande is the President and CEO of Omega Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines for...
13 Sep 202329min
Catalyzing the next generation of mRNA medicines, Joseph Payne, Founder, Pres. & CEO, Arcturus Tx
Synopsis: Joseph Payne is the Founder, President and CEO of Arcturus Therapeutics, a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and ...
6 Sep 202329min
Advancing muscle biology, Robert Blum, Pres. & CEO, & Fady Malik, EVP, Research & Dev., Cytokinetics
Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, a late-stage biopharmaceutical company committed to developing potenti...
30 Aug 202329min
Transforming the treatment of neuromuscular diseases, James McArthur, CEO, PepGen
Synopsis: James McArthur is the CEO of PepGen, a biotech company creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious ge...
23 Aug 202328min
Conquering new frontiers in cell therapy, Paul Lammers, CEO, Triumvira Immunologics
Synopsis: Paul Lammers, M.D., is the CEO of Triumvira Immunologics, a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the...
16 Aug 202333min
Next-gen immunotherapies for cancer, Andrew Scharenberg, Co-founder & CEO, Umoja Biopharma
Synopsis: Andrew Scharenberg is the Co-founder and CEO of Umoja Biopharma, a company pioneering the future of immunotherapy by reprogramming T cells in vivo. Umoja’s groundbreaking integrated platfor...
9 Aug 202332min
